secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001628280-26-024101
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo completes sale of Biosecurity segment to Tower Biosecurity, retains 20% stake
--------------------------------------------------------------------------------

- On April 3, 2026, Ginkgo contributed all Biosecurity equity to Tower Biosecurity (Perimeter Systems) for ~20% of buyer's fully diluted shares.
- Biosecurity will be reported as discontinued operations starting Q1 2026; pro forma results show reduced operating losses.
- Pro forma 2025 net loss improved to $287.8M from $312.8M; 2024 loss improved to $507.6M from $547.0M.
- The retained 20% stake will be equity-method accounted; preliminary valuation of $12.3M.
- Ginkgo and Tower entered a Transition Services Agreement for temporary services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828026024101/0001628280-26-024101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828026024101/dna-20260403.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-024101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer